The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Open accessAbstract
Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor analysis from patients with metastatic melanoma receiving vaccine and cytokine therapies suggested a paradigm of two broad phenotypes characterized by the presence or absence a T cell-inflamed tumor.”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [7]
In the citing paper
“Tumors from patients showing sustained treatment response predominately demonstrate a T cell-inflamed tumor microenvironment prior to, or early on, treatment.”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137 · cited 1×
“Previous work has shown that antigen-presenting cells in the tumor microenvironment can be tolerogenic (37), and that some cytokines abundant in the tumor, such as IL-10, can inhibit dendritic cell activation and result in T cell anergy (38).”
BackgroundRetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Although direct CCL22 production by tumor cells in other cancer types also has been suggested (34), we did not detect CCL22 mRNA expression in a series of melanoma cell lines, arguing that in the melanoma context, it is likely derived from infiltrating nontumor stromal cells (13).”
BackgroundBrahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · cited 1×
“Clinical strategies to counter these immunosuppressive pathways are currently being evaluated, already with encouraging early-phase clinical trial results (10–12).”
BackgroundPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · cited 1×
“IDO is a tryptophanmetabolizing enzyme that has been shown to contribute to peripheral immunologic tolerance (25).”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“…in mouse models include extrinsic suppression of CD8 + effector cells by CD4 + CD25 + FoxP3 + regulatory T cells (T regs ) (6), metabolic deregulation via tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO) (7), and engagement of the inhibitory receptor PD-1 by the ligand PD-L1/B7-H1 (8, 9).”
BackgroundTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · cited 2×
“It has been speculated that clinical response to antibodies targeting the PD-L1/PD-1 interaction may end up being restricted to cases in which PD-L1 expression is associated with a CD8 + T cell infiltrate and therefore is likely blunting host immunity (32).”
Background
Cited by
Sorted by citations
Items 401–500 of 1,001
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 110
miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer
Lou, Q., Liu, R., Yang, X., Li, W., Huang, L. J., Wei, L., Tan, H., Xiang, N., Chan, K., Chen, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0691-0 · Cited by 103
The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses
Westrich, J. A., Vermeer, D. W., Colbert, P. L., Spanos, W. C., & Pyeon, D. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23188 · Cited by 99
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 107
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 108
“Activation of the canonical WNT-β-catenin signaling pathway in melanoma cells has been shown to correlate with suppression of the chemokine CCL4, reduced T cell infiltration and resistance to anti-PDL1 and anti-CTLA-4 mAb-based therapy [151].”
BackgroundFrancis, D. M., & Thomas, S. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.011 · Cited by 100
Lü, J., Chen, X., Huang, H., Zhao, F., Wang, F., Liu, X., & Li, X. (2018) · Head & Neck · doi:10.1002/hed.25104 · Cited by 100
“In addition, CD81CTLs may upregulate the expression of PD-L1 and indoleamine-2,3-dioxygenase in tumor cells, recruit Tregs in the tumor microenvironment, and then promote tumor immune escape by the production of CCL22 and interferon-g.(7,15,16) Some discrepancy exists for the prognostic significance of Treg cells.”
BackgroundConvergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 106
“In fact, CD8 + T cells themselves may promote T reg cell responses 224 , indicating a negative-feedback loop that limits antitumour immunity.”
Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 103
Jin, J., & Zhao, Q. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00629-y · Cited by 103
A Checkpoint‐Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy
Li, Q., Zhao, Z., Qin, X., Zhang, M., Du, Q., Li, Z., & Luan, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104630 · Cited by 100
Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 106
“Multiple types of human cancer including non-small cell lung cancer (NSCLC) (33,34), melanoma (35), renal cell carcinoma (36), prostate cancer (37), and gastric cancer have been verified to highly express PD-L1 (38).”
Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2021) · Clinical and Translational Oncology · doi:10.1007/s12094-020-02421-8 · Cited by 84
Budczies, J., Bockmayr, M. L., Denkert, C., Klauschen, F., Gröschel, S., Darb‐Esfahani, S., Pfarr, N., Leichsenring, J., Onozato, M. L., Lennerz, J. K., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22365 · Cited by 99
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 100
Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy
Lee, J., Le, Q., Yang, G., & Oh, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119359 · Cited by 99
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 101
“The decreased infiltration of CD8+ T cells is also regulated by immune suppressive mechanisms, mediated via indoleamine-2, 3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3+ Tregs [29].”
BackgroundZakharia, Y., McWilliams, R. R., Rixe, O., Drabick, J. J., Shaheen, M. F., Grossmann, K. F., Kolhe, R. B., Pacholczyk, R., Sadek, R., Tennant, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002057 · Cited by 100
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Borcoman, É., Rochère, P. D. L., Richer, W., Vacher, S., Chemlali, W., Krucker, C., Sirab, N., Radvanyi, F., Allory, Y., Pignot, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581556 · Cited by 96
Alissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 98
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
cGAS-STING pathway in oncogenesis and cancer therapeutics
Hoong, B. Y. D., Gan, Y., Liu, H., & Chen, E. S. (2020) · Oncotarget · doi:10.18632/oncotarget.27673 · Cited by 106
Choi, B., Moon, H., Hong, S. J., Shin, C., Do, Y., Ryu, S., & Kang, S. (2016) · ACS Nano · doi:10.1021/acsnano.5b08084 · Cited by 98
Morandi, F., Morandi, B., Horenstein, A. L., Chillemi, A., Quarona, V., Zaccarello, G., Carrega, P., Ferlazzo, G., Mingari, M. C., Moretta, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4693 · Cited by 96
Zaravinos, A., Roufas, C., Nagara, M., de Lucas, B., Oblovatskaya, M., Efstathiades, C., Dimopoulos, C., & Ayiomamitis, G. D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1372-z · Cited by 97
“response in CYT-high colorectal tumors, similar to melanoma [53] and prostate cancer [28, 30] elicits multiple”
BackgroundImproving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Zhang, B., & Cheng, P. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01275-6 · Cited by 102
Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8636 · Cited by 97
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 103
Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 101
Kang, T., Huang, Y., Zhu, Q., Cheng, H., Pei, Y., Feng, J., Xu, M., Jiang, G., Song, Q., Jiang, T., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.033 · Cited by 98
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J. P., Filia, A., O'Shea, S. J., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
Kwak, G., Kim, D., Nam, G., Wang, S. Y., Kim, I.-S., Kim, S. H., Kwon, I. C., & Yeo, Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b04717 · Cited by 95
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 94
Albu, D. I., Wang, Z., Huang, K., Wu, J., Twine, N. C., Leacu, S., Ingersoll, C., Parent, L. A., Lee, W., Liu, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338239 · Cited by 94
Xie, K., Xu, L., Wu, H., Liao, H., Luo, L., Liao, M., Gong, J., Deng, Y., Yuan, K., Wu, H. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404214 · Cited by 96
Deng, H., Tan, S., Gao, X., Zou, C., Xu, C., Tu, K., Song, Q., Fan, F., Huang, W., & Zhang, Z. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.004 · Cited by 95
Solid stress impairs lymphocyte infiltration into lymph-node metastases
Jones, D., Wang, Z., Chen, I. X., Zhang, S., Banerji, R., Lei, P., Zhou, H., Xiao, V., Kwong, C., van Wijnbergen, J. W., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00766-1 · Cited by 93
Ascierto, P. A., Casula, M., Bulgarelli, J., Pisano, M., Piccinini, C., Piccin, L., Cossu, A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44475-6 · Cited by 102
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
Aoki, T., Hino, M., Koh, K., Kyushiki, M., Kishimoto, H., Arakawa, Y., Hanada, R., Kawashima, H., Kurihara, J., Shimojo, N., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26018 · Cited by 90
Shigemori, T., Toiyama, Y., Okugawa, Y., Yamamoto, A., Yin, C., Narumi, A., Ichikawa, T., Ide, S., Shimura, T., Fujikawa, H., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07112-x · Cited by 93
Platelet-armored nanoplatform to harmonize janus-faced IFN-γ against tumor recurrence and metastasis
Li, Q., Zhou, Y., He, W., Ren, X., Zhang, M., Jiang, Y., Zhou, Z., & Luan, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.020 · Cited by 93
Immunotherapy for Esophageal and Gastric Cancer
Kelly, R. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175231 · Cited by 93
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
Tanese, K., Hashimoto, Y., Berkova, Z., Wang, Y., Samaniego, F., Lee, J. E., Ekmekçioglu, S., & Grimm, E. A. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.204 · Cited by 91
Zhou, F., Krishnamurthy, J., Wei, Y., Li, M., Hunt, K., Johanning, G., Cooper, L., & Wang-Johanning, F. (2015) · Oncoimmunology · doi:10.1080/2162402x.2015.1047582 · Cited by 81
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
Leung, J., & Suh, W. (2014) · Immune Network · doi:10.4110/in.2014.14.6.265 · Cited by 92
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 93
Gomez‐Aleza, C., Nguyen, B., Yoldi, G., Ciscar, M., Barranco, A., Hernández-Jiménez, E., Maetens, M., Salgado, R., Zafeiroglou, M., Pellegrini, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20138-8 · Cited by 92
Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation
Carter, T. J., Agliardi, G., Lin, F., Ellis, M. J., Jones, C. L., Robson, M. P., Richard-Loendt, A., Southern, P., Lythgoe, M. F., Thin, M. Z., et al. (2021) · Small · doi:10.1002/smll.202005241 · Cited by 92
Wirsing, A. M., Ervik, I. K., Seppola, M., Uhlin‐Hansen, L., Steigen, S. E., & Hadler‐Olsen, E. (2018) · Modern Pathology · doi:10.1038/s41379-018-0019-5 · Cited by 95
Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 90
Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L., de Albuquerque, C. G. P., dos Reis, R. B., Graham, C. H., Berman, D. M., Siemens, D. R., Squire, J. A., et al. (2019) · The Prostate · doi:10.1002/pros.23808 · Cited by 90
Liao, H., Zhang, Z., Chen, J., Liao, M., Xu, L., Wu, Z., Yuan, K., Song, B., & Zeng, Y. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07815-9 · Cited by 90
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 93
“20 21 24 However, few studies have investigated the events that lead to low immune infiltration in TNBC.”
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 95
“Importantly, IDO upregulation in the TME was shown to be dependent on CD8+T-cell infiltration and IFN-γ stimulation, supporting an adaptive mechanism of resistance [140].”
BackgroundWu, X., Giobbie‐Hurder, A., Liao, X., Lawrence, D. P., McDermott, D. F., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0084 · Cited by 92
Boxberg, M., Steiger, K., Lenze, U., Rechl, H., von Eisenhart‐Rothe, R., Wörtler, K., Weichert, W., Langer, R., & Specht, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1389366 · Cited by 92
CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
Zhang, C., Li, Z., Xu, L., Che, X., Wen, T., Fan, Y., Li, C., Wang, S., Cheng, Y., Wang, X., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4384-8 · Cited by 88
Fan, J., Lu, F., Qin, T., Peng, W., Zhuang, X., Li, Y., Hou, X., Fang, Z., Yang, Y., Guo, E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01570-0 · Cited by 93
“…immune activation (including antigen presentation and chemokine process genes) 27 and immune evasion (including immune checkpoint-associated genes) 28 , as well as decreased immune cells and elevated immune excluded associated cell types (mesenchymal stem cells, myocytes and keratinocytes) were…”
BackgroundRelationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma
Huang, C.-Y., Wang, Y., Luo, G., Han, F., Li, Y.-Q., Zhou, Z., & Xu, G.-L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000187 · Cited by 89
Bao, R., Wang, Y., Lai, J., Zhu, H., Zhao, Y., Li, S., Li, N., Huang, J., Yang, Z., Wang, F., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00997 · Cited by 88
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Röhrig, U. F., Reynaud, A., Majjigapu, S. R., Vogel, P., Pojer, F., & Zoete, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00942 · Cited by 86
Recent Update of HDAC Inhibitors in Lymphoma
Chen, I., Sethy, B., & Liou, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576391 · Cited by 83
“Thus, targeting CD8 + t cell could be a solution to reduction of tumor immunity (Dong and Chen, 2003; Harlin et al., 2009; Spranger et al., 2013).”
BackgroundGuan, L., Wu, B., Li, T., Beer, L. A., Sharma, G., Li, M., Lee, C. N., Liu, S., Yang, C., Huang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31713-6 · Cited by 87
“VHS FYVE UIM PSAP CB 1-1 39 15 5-2 21 25 7-2 77 34 8-3 51 70 4-7 77 CC 46 9-5 53 i (1-777) 100 70”
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Spaapen, R. M., Leung, M. Y. K., Fuertes, M. B., Kline, J. P., Zhang, L., Zheng, Y., Fu, Y., Luo, X., Cohen, K. S., & Gajewski, T. F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401109 · Cited by 86
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
Bassiri, H., Benavides, A. D., Haber, M., Gilmour, S. K., Norris, M. D., & Hogarty, M. D. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.06 · Cited by 87
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L. P., & Gajewski, T. F. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 87
Zhu, Q., Cai, M.-Y., Chen, C.-L., Hu, H., Lin, H., Li, M., Weng, D., Zhao, J.-J., Guo, L., & Xia, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1312240 · Cited by 85
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 88
Park, I. H., Kong, S., Ro, J. Y., Kwon, Y., Kang, J. H., Mo, H. J., Jung, S.-Y., Lee, S., Lee, K. S., Kang, H.-S., et al. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.006 · Cited by 86
Li, A., Barsoumian, H. B., Schoenhals, J. E., Cushman, T. R., Caetano, M. S., Wang, X., Valdecanas, D. R., Niknam, S., Younes, A. I. A., Li, G., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.005 · Cited by 83
Kleponis, J., Skelton, R. A., & Zheng, L. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0046 · Cited by 91
Jin, P., Zhao, Y., Liu, H., Chen, J., Ren, J., Jin, J., Bedognetti, D., Liu, S., Wang, E., Marincola, F. M., et al. (2016) · Scientific Reports · doi:10.1038/srep26345 · Cited by 84
Immune checkpoint modulation: Rational design of combination strategies
Zamarin, D., & Postow, M. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.003 · Cited by 85
Krishna, S., Ulrich, P. R., Wilson, E., Parikh, F., Narang, P., Yang, S., Read, A. K., Kim‐Schulze, S., Park, J. G., Posner, M. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0163 · Cited by 85
Lin, G., Fan, X., Zhu, W., Huang, C., Zhuang, W., Xu, H., Lin, X., Hu, D., Huang, Y., Jiang, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20233 · Cited by 83
Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1248 · Cited by 85
Ness, N., Andersen, S., Rakaee, M., Nordbakken, C. V., Valkov, A., Paulsen, E., Nordby, Y., Bremnes, R. M., Dønnem, T., Busund, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15817 · Cited by 81
He, W., Wang, S., Yan, J., Qu, Y., Jin, L., Sui, F., Li, Y., You, W., Yang, G., Yang, Q., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807736 · Cited by 82
Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy
Zhao, L., Zheng, R., Liu, L., Chen, X., Guan, R., Ni, Y., Chen, A., Yu, X., Cheng, H. B., & Li, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120970 · Cited by 81
Wang, K., Jiang, M., Zhou, J., Liu, Y., Zong, Q., & Yuan, Y. (2022) · ACS Nano · doi:10.1021/acsnano.1c08232 · Cited by 82
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115152 · Cited by 88
Mishra, A. K., Kadoishi, T., Wang, X., Driver, E., Chen, Z., Wang, J. H., & Wang, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.13228 · Cited by 86
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 81
Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
Yokoyama, S., Miyoshi, H., Nakashima, K., Shimono, J., Hashiguchi, T., Mitsuoka, M., Takamori, S., Akagi, Y., & Ohshima, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0434 · Cited by 81
PD-L1 Expression in Tumor Metastasis is Different Between Uveal Melanoma and Cutaneous Melanoma
Javed, A., Arguello, D., Johnston, C., Gatalica, Z., Terai, M., Weight, R. M., Orloff, M. M., Mastrangelo, M. J., & Sato, T. (2017) · Immunotherapy · doi:10.2217/imt-2017-0066 · Cited by 81
Cariani, E., & Missale, G. (2019) · Liver International · doi:10.1111/liv.14192 · Cited by 83
Rekoske, B. T., Smith, H. A., Olson, B. M., Maricque, B. B., & McNeel, D. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0206 · Cited by 81
Friedman, K. A., Brodsky, A. S., Lu, S., Wood, S., Gill, A. J., Lombardo, K. A., Yang, D., & Resnick, M. B. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.54 · Cited by 84
Myeloid-derived suppressor cells and tumor escape from immune surveillance
Umansky, V., Blattner, C., Fleming, V., Hu, X., Gebhardt, C., Altevogt, P., & Utikal, J. S. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0597-6 · Cited by 81
In-situ tumor vaccination: Bringing the fight to the tumor
Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J., & Kohrt, H. E. K. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1049779 · Cited by 80
Byrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
“Solid tumor data suggest that malignant tissue also expresses and can upregulate inhibitory signals that suppress T cell activation and reduce immunogenicity [29,30].”
BackgroundMSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
Rodriquenz, M. G., Roviello, G., D’Angelo, A., Lavacchi, D., Roviello, F., & Połom, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051427 · Cited by 83
PDL1 expression is an independent prognostic factor in localized GIST
Bertucci, F., Finetti, P., Mamessier, É., Pantaleo, M. A., Astolfi, A., Ostrowski, J., & Birnbaum, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002729 · Cited by 79
Huang, K. C., Chiang, S., Ke, T., Chen, T.-W., You, Y., Chen, W. T., & Chao, K. S. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33927-5 · Cited by 86
Anz, D., Rapp, M., Eiber, S., Koelzer, V. H., Thaler, R., Haubner, S., Knott, M. M. L., Nagel, S., Golić, M., Wiedemann, G. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3499 · Cited by 80
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 80
Kunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R. H. J., Sleijfer, S., & Debets, R. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00363 · Cited by 77
Parra, E. R., Villalobos, P. A., Zhang, J., Behrens, C., Mino, B., Swisher, S. G., Sepesi, B., Weissferdt, A., Kalhor, N., Heymach, J. V., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.002 · Cited by 74
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
Metadata
- Authors
- Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Spranger, Stefani
- Spaapen, Robbert M.
- Gajewski, Thomas F.
- Venue
- Science Translational Medicine
- Published
- 2013-08-28
- Volume
- 5
- Issue
- 200
- Pages
- 200ra116-200ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4136707
- OpenAlex
- W2136731993
- Cited by
- 1,677
- References
- 50
- Citations by year
- 2026: 49 · 2025: 76 · 2024: 112 · 2023: 122 · 2022: 136 · 2021: 173 · 2020: 158 · 2019: 162 · 2018: 171 · 2017: 176 · 2016: 155 · 2015: 111 · 2014: 70 · 2013: 6
- FWCI
- 61.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA127475, R01CA118153)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, tumor microenvironment, PD-L1, indoleamine 2,3-dioxygenase, regulatory T cells, CD8+ T cells, immunosuppression, immune checkpoint, interferon-gamma, cancer immunotherapy, tumor immune evasion
- MeSH terms
- Animals, Humans, Interferon-gamma, Lymphocyte Activation, Melanoma, Melanoma, Experimental, Neoplasm Metastasis, Up-Regulation, CD8-Positive T-Lymphocytes, Chemokines, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
